Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application

January 26, 2024

https://www.globenewswire.com/news-release/2024/01/26/2817840/0/en/Apellis-Announces-Negative-CHMP-Opinion-for-Pegcetacoplan-for-GA-in-the-European-Union-and-Plans-to-Seek-Re-Examination-of-Application.html

WALTHAM, Mass., Jan. 26, 2024 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq:APLS) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a negative opinion on the marketing authorization application (MAA) of intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). As previously announced, this opinion was expected based on a negative trend vote following an oral explanation meeting in December 2023. Apellis plans to seek immediate re-examination of its application.

Read more at globenewswire.com

Related news for (APLS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.